The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward

Area of Science:

• Neurology
• Clinical Medicine
• Public Health

Background:

• Comorbidity is highly prevalent in individuals with multiple sclerosis (MS) across all disease stages.
• Significant advancements in understanding the link between comorbidity and MS outcomes have occurred over the past 15 years.
• Comorbidity negatively impacts relapses, disability progression, quality of life, healthcare utilization, and mortality in MS patients.

Purpose of the Study:

• To highlight the substantial adverse effects of comorbidity on multiple sclerosis (MS) patient outcomes.
• To emphasize the critical need for effective comorbidity prevention and treatment strategies in the MS population.
• To outline the essential components required for optimizing comorbidity management in individuals with MS.

Main Methods:

• Review and synthesis of recent research on comorbidity in multiple sclerosis.
• Analysis of the impact of comorbidity on key MS outcomes.
• Identification of current challenges and future directions in MS comorbidity care.

Main Results:

• Comorbidity is associated with increased relapses, faster disability progression, and reduced quality of life in MS.
• Higher healthcare resource utilization and increased mortality rates are linked to comorbidity in MS patients.
• Current understanding underscores the pervasive negative influence of co-occurring conditions on the MS disease course.

Conclusions:

• Effective management of comorbidity is essential for improving the overall health and well-being of people with MS.
• Future efforts should focus on developing tailored interventions and optimal care models for comorbidity in MS.
• The development of appropriate tools for comorbidity evaluation is necessary for better patient management.